» Articles » PMID: 20838650

Pediatric Visceral Leishmaniasis in Albania: a Retrospective Analysis of 1,210 Consecutive Hospitalized Patients (1995-2009)

Overview
Date 2010 Sep 15
PMID 20838650
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Little information is available about infantile visceral leishmaniasis (VL) in Albania as regards incidence, diagnosis and management of the disease.

Methodology/principal Findings: Demographic data, clinical and laboratory features and therapeutic findings were considered in children admitted to University Hospital of Tirana from 1995 to 2009, and diagnosed as having VL. The diagnosis was based on bone-marrow microscopy/culture in 77.5% of patients, serology in 16.1%, and ex juvantibus in 6.4%. A total of 1,210 children were considered, of whom 74% came from urbanized areas. All patients were in the age range 0-14 years, with a median of 4 years. Hepatosplenomegaly was recorded in 100%, fever in 95.4% and moderate to severe anemia in 88% of cases. Concomitant conditions were frequent: 84% had bronchopneumonia; diarrhea was present in 27%, with acute manifestations in 5%; 3% had salmonellosis. First-line therapy was meglumine antimoniate for all patients, given at the standard Sb(v) dosage of 20 mg/kg/day for 21 to 28 days. Two children died under treatment, one of sepsis, the other of acute renal impairment. There were no cases of primary unresponsiveness to treatment, and only 8 (0.67%) relapsed within 6-12 months after therapy. These patients have been re-treated with liposomal amphotericin B, with successful cure.

Conclusions: Visceral leishmaniasis in pediatric age is relatively frequent in Albania; therefore an improvement is warranted of a disease-specific surveillance system in this country, especially as regards diagnosis. Despite recent reports on decreased responses to antimonial drugs of patients with Mediterranean VL, meglumine antimoniate treatment appears to be still highly effective in Albania.

Citing Articles

A Retrospective Study of Genetic Characterization in Suspected Visceral Leishmaniasis Cases in Greece, 2005 to 2020.

Evangelidou M, Makka S, Papadogiannaki I, Koutantou M, Tegos N, Mpimpa A Pathogens. 2024; 13(8).

PMID: 39204288 PMC: 11357202. DOI: 10.3390/pathogens13080688.


The estimated distribution of autochthonous leishmaniasis by Leishmania infantum in Europe in 2005-2020.

Maia C, Conceicao C, Pereira A, Rocha R, Ortuno M, Munoz C PLoS Negl Trop Dis. 2023; 17(7):e0011497.

PMID: 37467280 PMC: 10389729. DOI: 10.1371/journal.pntd.0011497.


Visceral leishmaniasis in Kosovo: A case of misdiagnosis and diagnostic challenges.

Tolaj I, Mehmeti M, Gashi H, Berisha F, Gashi V, Fejza H IDCases. 2023; 32:e01768.

PMID: 37131489 PMC: 10149197. DOI: 10.1016/j.idcr.2023.e01768.


Hepatomegaly Associated with Non-Obstructive Sinusoidal Dilation in Experimental Visceral Leishmaniasis.

Maeda K, Sadoughi S, Morimoto A, Uchida K, Chambers J, Sanjoba C Pathogens. 2021; 10(11).

PMID: 34832512 PMC: 8625948. DOI: 10.3390/pathogens10111356.


Pediatric visceral leishmaniasis in Tartous, Syria.

Hamwi A, Mohammad A, Hamwi S, Mohammad R, Shahin K Avicenna J Med. 2021; 10(4):223-226.

PMID: 33437694 PMC: 7791284. DOI: 10.4103/ajm.ajm_168_20.


References
1.
Laguna F, Videla S, Jimenez-Mejias M, Sirera G, Torre-Cisneros J, Ribera E . Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother. 2003; 52(3):464-8. DOI: 10.1093/jac/dkg356. View

2.
Desjeux P . The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg. 2001; 95(3):239-43. DOI: 10.1016/s0035-9203(01)90223-8. View

3.
Gradoni L, Gramiccia M, Scalone A . Visceral leishmaniasis treatment, Italy. Emerg Infect Dis. 2004; 9(12):1617-20. PMC: 3034325. DOI: 10.3201/eid0912.030178. View

4.
Cascio A, Di Martino L, Occorsio P, Giacchino R, Catania S, Gigliotti A . A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. J Antimicrob Chemother. 2004; 54(1):217-20. DOI: 10.1093/jac/dkh279. View

5.
Gramiccia M, Gradoni L . The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol. 2005; 35(11-12):1169-80. DOI: 10.1016/j.ijpara.2005.07.001. View